LAHRS Content 2023-LAHRS/APHRS Risk Stratification 2023

Video Transcription

Video Summary

In summary, the presentation covered the risk stratification and therapy for Arrhythmo-Gynic Right Ventricular Cardiomyopathy (ARVC). Key points discussed included the genetic basis of ARVC, second-hit factors leading to disease onset, lifestyle modifications to reduce risk, medications for heart failure management, ventricular arrhythmia treatment options, and the role of ablation therapy for ventricular arrhythmias. Risk stratification models were presented, highlighting factors such as male sex, age of onset, ECG findings, and PVC burden as predictors of ventricular arrhythmias and sudden cardiac death in ARVC patients. The importance of exercise restriction, lifestyle modifications, beta-blockers, amiodarone, ICD implantation, and the potential benefits of flecainide and ablation therapy in managing ARVC were emphasized. The presentation concluded by noting the need for further research to validate risk calculators for Asian populations with different genetic backgrounds and regional phenotypes of the disease. It also highlighted ongoing advancements in treatment strategies for ARVC.

Keywords

Arrhythmo-Gynic Right Ventricular Cardiomyopathy

ARVC

risk stratification

therapy

genetic basis

second-hit factors

lifestyle modifications

medications

ventricular arrhythmia

ablation therapy

risk calculators